LL-37

LL-37 (Cathelicidin fragment) is a cathelicidin peptide (37 amino acids). The HEIVE catalog describes it as: The body's own antimicrobial peptide, cut from cathelicidin. It kills pathogens outright and then tells the immune system what to do next. It is also known as Cathelicidin and CAP-18.

HEIVE groups LL-37 under infection defense, immune balance, infection recovery, inflammation and tissue repair. These catalog categories are not approved indications or evidence that treatment works. See the product-specific regulatory answer below.

No matching FDA product was identified for LL-37 under the searched names in the October 6, 2026 Drugs@FDA snapshot. This name search does not establish worldwide approval status or exclude differently named products. FDA describes safety concerns or insufficient safety information for the corresponding substance on its compounding-risk page; that listing is not a drug approval.

• FDA product data (October 6, 2026)
• FDA compounding safety information

The HEIVE editorial risk summary for LL-37 lists: Injection-site inflammation is common and can be marked; histamine release causes flushing. Longer-term concerns: At high concentration it is cytotoxic to human cells too. The window is narrow and unmapped in humans. This is not a complete or clinically reviewed safety assessment; risks depend on the product, route and population.

LL-37 has no single onset time established by this catalog. The editorial timeline starts with “Days 1–7”. These are illustrative model or editorial milestones, not clinically validated outcome predictions.

HEIVE's illustrative catalog entry for LL-37: 100–200 mcg subcutaneously daily for 7–14 days. This is not a verified study range or a prescription. A dose cannot be transferred between products, routes or indications; use the specific approved label and the prescribing clinician's instructions where applicable.

The catalog classifies LL-37 as mainly preclinical. Its paper-count snapshot is not a live PubMed search, a count of controlled human trials or proof of safety. This FAQ has not independently validated the catalog's clinical literature claims.

The source catalog lists topical for LL-37. A listed form is not evidence of an approved or effective treatment.

Preparation of LL-37 depends on the exact labeled product. Follow its instructions for formulation, diluent, route and storage. A generic powder recipe must not be applied to a prefilled, ready-to-use or differently formulated product. The catalog's mixing example does not establish sterility or stability.

Storage for LL-37 depends on the specific formulation (injectable and topical in the source catalog). Follow the product's labeled temperature, light protection and expiry or discard instructions. A general refrigerator or 28-day rule does not establish stability or sterility for every preparation.

The HEIVE editorial summary for LL-37: None described. Short courses are the convention. This summary is not a clinically validated prediction of tolerance or withdrawal for an individual.

LL-37 and KPV share the catalog categories inflammation, gut healing and tissue repair. LL-37: The body's own antimicrobial peptide, cut from cathelicidin. It kills pathogens outright and then tells the immune system what to do next. KPV: The anti-inflammatory tail of α-MSH without the pigmentation activity, studied mostly in colitis models. This is a catalog comparison, not a head-to-head clinical result or a recommendation to substitute treatments.

• View KPV

The HEIVE editorial summary highlights: Wound-healing and vessel-formation effects turned up in work designed to measure bacterial killing. The cited study, population and formulation must be checked before treating this summary as a clinical finding; this FAQ does not supply a verified research citation for it.